(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has retained Sheppard Mullin, Richter and Hampton LLC (“Sheppard Mullin”) and RHK Capital (“RHK”).
Sheppard Mullin will advise the Company on U.S. general corporate matters and securities law as the Company looks towards the U.S. capital markets. The Company has also engaged RHK, a leading U.S. boutique investment bank which specializes in small and middle market financing transactions.